TITLE

Managing high-cost biotechnology products

AUTHOR(S)
Wong, Dorothy H.; Yang, Peggy
PUB. DATE
June 2003
SOURCE
American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track compliance with the order form.
ACCESSION #
10030402

 

Related Articles

  • P & T PORTFOLIO.  // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16 

    Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.

  • Drotrecogin alfa (activated). Caron, Michael R.; Kuti, Joseph L.; Quintiliani, Richard; White, C. Michael // Formulary;Nov2001, Vol. 36 Issue 11, p784 

    Drotrecogin alfa (activated), a recombinantly produced preparation of human activated protein C, reduces the inflammatory, procoagulant, and antifibrinolytic host response to infection. At press time, an FDA advisory committee was split over whether to recommend it for approval for treating...

  • Lilly Hopes Sepsis Drug Will Cushion Prozac Expiry. Jarvis, Lisa // Chemical Market Reporter;11/27/2000, Vol. 258 Issue 22, p5 

    Reports on the development of a recombinant human activated protein C drug for the treatment of sepsis, manufactured by Eli Lilly & Co. Estimated number of people in the United States who suffered from sepsis annually; Benefits given by the drug to the company.

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • Severe Sepsis and Septic Shock in 2012: What Have We Learned? Pierson, Daniel J. // Infectious Disease Alert;Feb2012, Vol. 31 Issue 5, p53 

    The article examines the progress in the treatment of sepsis, severe sepsis and septic shock. The voluntary market withdrawal of Xigris or activated protein C (APC) is explained in terms of lack of evidence of efficacy and substantial risk for adverse effects. The effectiveness of other new...

  • Administration of protein C concentrates in patients without congenital deficit: a systematic review of the literature. SILVETTI, SIMONA; CRIVELLARI, MARTINA; MUCCHETTI, MARTA; TADDEO, DAIANA; FRANCO, ANNALISA; LANDONI, GIOVANNI; ZANGRILLO, ALBERTO // Signa Vitae;Oct2013, Vol. 8 Issue 2, p15 

    Endogenous protein C levels are frequently decreased in septic patients, probably due to increased conversion to activated protein C. Protein C levels inversely correlate with morbidity and mortality of septic patients regardless of age, infecting microorganisms, presence of shock, disseminated...

  • Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi. Levi, M. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.

  • Management challenge with drotrecogin alfa (activated). Vanscoy, Gordon J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS23 

    Clinical trial results for drotrecogin alfa (activated) are discussed in terms of potential effect on morbidity and total cost of care. Interdisciplinary collaboration is crucial for improving care in health systems; teamwork has been shown to improve outcomes in intensive care and reduce costs....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics